From the Department of Diagnostic and Interventional Radiology (C.K.K., K.S., S.S.) and Section of Biostatistics, Department of Diagnostic and Interventional Radiology (H.B.), University of Aachen, RWTH, Pauwelsstr 30, 52074 Aachen, Germany; and Department of Radiology, University of Bonn, Bonn, Germany (C.L., H.H.S.).
Radiology. 2017 May;283(2):361-370. doi: 10.1148/radiol.2016161444. Epub 2017 Feb 21.
Purpose To investigate the utility and accuracy of breast magnetic resonance (MR) imaging as a supplemental screening tool in women at average risk for breast cancer and to investigate the types of cancer detected with MR imaging screening. Materials and Methods This prospective observational study was conducted at two academic breast centers in women aged 40-70 years without breast cancer-associated risk factors (lifetime risk <15%). Between January 2005 and December 2013, women with at least minimal residual breast tissue (American College of Radiology categories A-D) and normal conventional imaging findings (screening mammography with or without screening ultrasonography [US]) were invited to undergo supplemental MR imaging screening. Outcome measures were supplemental cancer detection rates, interval cancer rates, and biologic profiles of MR imaging-detected additional cancers, as well as specificity and positive predictive value (PPV) of MR imaging screening. Tissue diagnoses or 2 years of follow-up were used to establish the reference standard. Results A total of 2120 women were recruited and underwent 3861 screening MR imaging studies, covering an observation period of 7007 women-years. Breast MR imaging depicted 60 additional breast cancers (ductal carcinoma in situ, n = 20; invasive carcinoma, n = 40) for an overall supplemental cancer detection rate of 15.5 per 1000 cases (95% confidence interval [CI]: 11.9, 20.0). Forty-eight additional cancers were detected with MR imaging at initial screening (supplemental cancer detection rate, 22.6 per 1000 cases). During the 1741 subsequent screening rounds, 12 of 13 incident cancers were found with MR imaging alone (supplemental cancer detection rate, 6.9 per 1000 cases). One cancer was diagnosed with all three methods (mammography, US, and MR imaging), and none were diagnosed with mammography only or US only. Cancers diagnosed with MR imaging were small (median, 8 mm), node negative in 93.4% of cases, and dedifferentiated (high-grade cancer) in 41.7% of cases at prevalence screening and 46.0% of cases at incidence screening. No interval cancers were observed. MR imaging screening offered high specificity (97.1%; 95% CI: 96.5, 97.6) and high PPV (35.7%; 95% CI: 28.9, 43.1). Conclusion In women at average risk for breast cancer, MR imaging screening improves early diagnosis of prognostically relevant breast cancer. RSNA, 2017 Online supplemental material is available for this article.
目的 旨在探讨乳腺磁共振(MR)成像作为一种补充筛查工具在乳腺癌平均风险女性中的应用价值和准确性,并探讨 MR 成像筛查检测到的癌症类型。
材料与方法 本前瞻性观察性研究在两家学术性乳腺中心进行,纳入年龄在 40-70 岁、无乳腺癌相关危险因素(终生风险<15%)的女性。在 2005 年 1 月至 2013 年 12 月期间,对至少有少量残留乳腺组织(美国放射学院分类 A-D)且常规影像学检查结果正常(乳腺筛查 X 线摄影术联合或不联合乳腺筛查超声检查)的女性进行补充性 MR 成像筛查。主要观察指标为补充性癌症检出率、间期癌症发生率、MR 成像检出的额外癌症的生物学特征,以及 MR 成像筛查的特异性和阳性预测值(PPV)。组织学诊断或 2 年随访结果被用于建立参考标准。
结果 共纳入 2120 例女性,行 3861 次乳腺 MR 成像筛查,观察时间为 7007 例女性年。MR 成像共检出 60 例额外乳腺癌(导管原位癌 20 例,浸润性癌 40 例),总体补充性癌症检出率为 15.5/1000 例(95%置信区间:11.9,20.0)。48 例额外癌症在初始筛查时被 MR 成像检出(补充性癌症检出率为 22.6/1000 例)。在随后的 1741 次筛查中,13 例新发癌症中有 12 例仅通过 MR 成像检出(补充性癌症检出率为 6.9/1000 例)。1 例癌症通过所有 3 种方法(乳腺 X 线摄影术、超声检查和 MR 成像)检出,而无 1 例仅通过乳腺 X 线摄影术或超声检查检出。MR 成像检出的癌症较小(中位数 8 mm),93.4%的病例淋巴结阴性,41.7%的病例在患病率筛查时为去分化(高级别癌症),46.0%的病例在发病率筛查时为去分化。未发现间期癌症。MR 成像筛查具有很高的特异性(97.1%;95%CI:96.5,97.6)和很高的 PPV(35.7%;95%CI:28.9,43.1)。
结论 在乳腺癌平均风险女性中,MR 成像筛查可提高对具有预后意义的乳腺癌的早期诊断率。
放射学会,2017 年
网上补充材料为本研究的相关内容。